神经内分泌肿瘤的肽受体放射性核素治疗:激动剂、拮抗剂及替代方案
肽受体放射性核素治疗(PRRT)现已成为神经内分泌肿瘤(NET)的成熟治疗策略。基于NETTER-1试验,Luthatera®于2017年获批用于G1/G2 NET患者;NETTER-2试验的长期结果可能为晚期G2/G3患者的一线治疗开辟新选择。双示踪剂PET/CT及基于不同代谢途径、放射性核素或联合方案的替代策略正在讨论中,诊疗一体化(thera(g)nostic)概念有望用于筛选可能从不同影像引导治疗策略中获益的患者。
要点
- PRRT是NET的成熟治疗策略,基于NETTER-1试验Luthatera®于2017年获批用于G1/G2 NET患者。
- NETTER-2试验的长期结果可能为晚期G2/G3患者的一线治疗开辟新选择。
- 双示踪剂[18F]F-FDG/[68Ga]Ga-DOTA-SSA PET/CT在NET诊断和随访中的应用正在讨论中,可能成为强有力的预后工具。
核心结论
- PRRT是NET的成熟治疗策略,基于NETTER-1试验Luthatera®于2017年获批用于G1/G2 NET患者。
- NETTER-2试验的长期结果可能为晚期G2/G3患者的一线治疗开辟新选择。
- 双示踪剂PET/CT及基于不同代谢途径、放射性核素或联合方案的替代策略可能在未来为NET患者提供更多治疗选择,诊疗一体化概念是关键。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- PRRT首次开展已超过30年前,近年来基于临床试验中证实的疗效和安全性被纳入主要肿瘤学指南。
- NETTER-1试验后Luthatera®于2017年最终注册用于G1/G2 NET患者。
- NETTER-2试验的长期结果可能为晚期G2/G3患者的一线治疗开辟新选择。
- 联合治疗的协同效应知识增长可能为NET患者提供替代(再)治疗选择,以制定个体化治疗策略。
- 双示踪剂[18F]F-FDG/[68Ga]Ga-DOTA-SSA PET/CT用于NET诊断和随访正在讨论中,可能成为强有力的预后工具。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy for patients with neuroendocrine tumors (NET). First performed already more than 30 years ago, PRRT was incorporated only in recent years into the major oncology guidelines, based on its proven efficacy and safety in clinical trials. Following the phase 3 NETTER-1 trial, which led to the final registration of the radiopharmaceutical Luthatera® for G1/G2 NET patients in 2017, the long-term results of the phase 3 NETTER-2 trial may pave the way for a new treatment option also for advanced G2/G3 patients as first-line therapy. The growing knowledge about the synergistic effect of combined therapies could also allow alternative (re)treatment options for NET patients, in order to create a tailored treatment strategy. The evolving thera(g)nostic concept could be applied for the identification of patients who might benefit from different image-guided treatment strategies. In this scenario, the use of dual tracer PET/CT in NET patients, using both [18F]F-FDG/[68Ga]Ga-DOTA-somatostatin analog (SSA) for diagnosis and follow-up, is under discussion and could also result in a powerful prognostic tool. In addition, alternative strategies based on different metabolic pathways, radioisotopes, or combinations of different medical approaches could be applied. A number of different promising "doors" could thus open in the near future for the treatment of NET patients - and the "key" will be thera(g)nostic!
引用
- Santo G, Di Santo G, Virgolini I, et al. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives. Semin Nucl Med. 2024. PMID: 38490913. doi:10.1053/j.semnuclmed.2024.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。